Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00354094 |
The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of [S,S]-Reboxetine in patients with pain after shingles.
Condition | Intervention | Phase |
---|---|---|
Pain |
Drug: [S,S]-Reboxetine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2B Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Postherpetic Neuralgia (PHN). |
Estimated Enrollment: | 600 |
Study Start Date: | November 2006 |
Study Completion Date: | October 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A6061030 |
Study First Received: | July 18, 2006 |
Last Updated: | November 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00354094 |
Health Authority: | United States: Food and Drug Administration |
Neuralgia, Postherpetic Herpes Zoster Neuralgia Pain Reboxetine |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Therapeutic Uses |
Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Agents Pharmacologic Actions Antidepressive Agents |